Search
EDI-200
go.drugbank.com/drugs/DB18188InvestigationalEDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
Categories: Amino Acids, Peptides, and Proteins, Intercellular Signaling Peptides and ProteinsDexelvucitabine
go.drugbank.com/drugs/DB12470InvestigationalDexelvucitabine has been used in trials studying the treatment of HIV Infections and Human Immunodeficiency Virus.
Categories: Nucleic Acids, Nucleotides, and NucleosidesRisuteganib
go.drugbank.com/drugs/DB14911InvestigationalRisuteganib is under investigation in clinical trial NCT02348918 (Phase 2 Randomized Clinical Trial of LuminateĀ® as Compared to AvastinĀ® in the Treatment of Diabetic Macular Edema).
Categories: Amino Acids, Peptides, and ProteinsGontivimab
go.drugbank.com/drugs/DB16179InvestigationalGontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus
Categories: Amino Acids, Peptides, and ProteinsDimethylcurcumin
go.drugbank.com/drugs/DB06133InvestigationalDimethylcurcumin is a synthetic chemical compound that is loosely based on a compound found in curcumin. It is a novel anti-androgen that enhances androgen receptor degradation.
1-benzylimidazole
go.drugbank.com/drugs/DB04581Experimental1-benzylimidazole, an N-imidazole derivative, has been shown to have strong cardiotonic activity.
ARCT-810
go.drugbank.com/drugs/DB17683InvestigationalARCT-810 is an mRNA replacement therapy that delivers ornithine transcarbamylase mRNA to hepatocytes.
Omburtamab
go.drugbank.com/drugs/DB15635Investigational[A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.
SS1(dsFv)-PE38
go.drugbank.com/drugs/DB17579InvestigationalSS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-small Cell Lung Adenocarcinoma